
Join to View Full Profile
1405 Clifton Rd NEAtlanta, GA 30322
Phone+1 404-785-1112
Fax+1 404-785-6288
Dr. Goldsmith is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 2002 - 2005
Children's Hospital of PhiladelphiaResidency, Pediatrics, 1999 - 2002
University of Alabama School of MedicineClass of 1999
Certifications & Licensure
GA State Medical License 2009 - 2027
PA State Medical License 2000 - 2010
American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan Start of enrollment: 2014 Jan 16
- 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat Start of enrollment: 2014 Jul 01
- MIBG With Dinutuximab +/- Vorinostat Start of enrollment: 2018 Sep 12
Roles: Contact
Publications & Presentations
PubMed
- 36 citationsA 3D Bioprinted in vitro Model of Neuroblastoma Recapitulates Dynamic Tumor-Endothelial Cell Interactions Contributing to Solid Tumor Aggressive Behavior.Liqun Ning, Jenny Shim, Martin L Tomov, Rui Liu, Riya Mehta
Advanced Science. 2022-08-01 - 24 citationsReduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistance.Jorida Çoku, David M Booth, Jan Skoda, Madison C Pedrotty, Jennifer Vogel
The EMBO Journal. 2022-04-19 - 10 citationsComprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care.Ryan J Summers, Sharon M Castellino, Christopher C Porter, Tobey J MacDonald, Gargi D Basu
JCO Precision Oncology. 2022-04-01
Press Mentions
- Clinical Trial May Change the Paradigm of Care for Patients with ALK-Driven High-Risk NeuroblastomaApril 4th, 2023
- Researchers Show Lorlatinib Is Safe and Effective for Patients with ALK-Driven Relapsed/Refractory High-Risk NeuroblastomaMarch 31st, 2023
- Targeted Cancer Treatment Helps Georgia Boy Facing Advanced NeuroblastomaOctober 5th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









